var data={"title":"Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/328510?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093662\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alka-Seltzer Plus Day Cold [OTC];</li>\n      <li>Comtrex Maximum Strength, Non-Drowsy Cold &amp; Cough [OTC];</li>\n      <li>GoodSense Daytime Cold &amp; Flu [OTC];</li>\n      <li>GoodSense Daytime Flu &amp; Severe Cold [OTC];</li>\n      <li>GoodSense Daytime [OTC];</li>\n      <li>GoodSense Pressure + Pain PE + Cough [OTC];</li>\n      <li>Mapap Multi-Symptom Cold [OTC];</li>\n      <li>Mucinex Fast-Max Congestion &amp; Headache [OTC];</li>\n      <li>Mucinex Fast-Max Severe Cold &amp; Sinus [OTC];</li>\n      <li>Sudafed PE Pressure+Pain+Cough [OTC];</li>\n      <li>Theraflu Daytime Severe Cold &amp; Cough [OTC];</li>\n      <li>Theraflu ExpressMax Daytime Severe Cold &amp; Cough [OTC];</li>\n      <li>Theraflu Multi-Symptom Severe Cold [OTC];</li>\n      <li>Tylenol Cold Max [OTC];</li>\n      <li>Vicks DayQuil Cold &amp; Flu Multi-Symptom [OTC];</li>\n      <li>Vicks Nature Fusion Cold &amp; Flu Multi-Symptom Relief [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093666\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Antitussive;</li>\n      <li>\n        Decongestant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093687\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cold and flu symptoms:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per capsule/tablet: Two capsules/tablets every 4 hours. Refer to product-specific labeling for maximum daily dosage; varies by product (maximum dosage range: 8 to 12 capsules/tablets [acetaminophen 2,600 to 3,900 mg/dextromethorphan 80 to 120 mg/phenylephrine 40 to 60 mg] per 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen  325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL (liquid/syrup): 30 mL every 4 hours. Refer to product-specific labeling for maximum daily dosage; varies by product (maximum: 120 to 180 mL  [acetaminophen 2,600 to 3,900 mg/dextromethorphan 80 to 120 mg/phenylephrine 40 to 60 mg] per 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen 500 mg/dextromethorphan 20 mg/phenylephrine 10 mg per packet (as powder for solution): One packet every 4 hours (maximum: 6 packets [acetaminophen 3,000 mg/dextromethorphan 120 mg/phenylephrine 60 mg] per 24 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen 650 mg/dextromethorphan 20 mg/phenylephrine 10 mg per packet (as powder for solution) or per 30 mL of syrup: One packet or 30 mL every 4 hours (maximum: 5 packets or 150 mL [acetaminophen 3,250 mg/dextromethorphan 100 mg/phenylephrine 50 mg] per 24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093686\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cold and flu symptoms:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 11 years: Vicks DayQuil Cold &amp; Flu Multi-Symptom Liquid:  Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maximum: 60 mL [acetaminophen 1,300 mg/dextromethorphan 40 mg/phenylephrine 20 mg]  per 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093688\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132843\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132844\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with hepatic impairment or active liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093692\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Comtrex Maximum Strength, Non-Drowsy Cold &amp; Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Pressure + Pain PE + Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mapap Multi-Symptom Cold: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [cool blast flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sudafed PE Pressure+Pain+Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Theraflu ExpressMax Daytime Severe Cold &amp; Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tylenol Cold Max: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vicks Nature Fusion Cold &amp; Flu Multi-Symptom Relief: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [DSC] [ethanol free, gluten free; honey flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, liquid filled, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alka-Seltzer Plus Day Cold: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Daytime: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Daytime Cold &amp; Flu: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex Fast-Max Congestion &amp; Headache: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex Fast-Max Severe Cold &amp; Sinus: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vicks DayQuil Cold &amp; Flu Multi-Symptom: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Daytime Cold &amp; Flu: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (237 mL, 354 mL) [alcohol free, gluten free; contains edetate disodium, polyethylene glycol, propylene glycol, sodium 7 mg/15 mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tylenol Cold Max: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (240 mL) [contains propylene glycol, sodium 5 mg/15 mL, sodium benzoate; citrus burst flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vicks DayQuil Cold &amp; Flu Multi-Symptom: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (180 mL, 300 mL) [ethanol free, sugar free; contains propylene glycol, sodium 50 mg/15 mL, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for solution, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Daytime Flu &amp; Severe Cold: Acetaminophen 500 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per packet (6s) [contains phenylalanine 22 mg/packet, potassium 10 mg/packet, and sodium 20 mg/packet; green tea and honey lemon flavors]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Theraflu Daytime Severe Cold &amp; Cough: Acetaminophen 650 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per packet (6s) [contains phenylalanine 14 mg/packet, potassium 10 mg/packet, and sodium 20 mg/packet; berry-green tea-menthol flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Theraflu Multi-Symptom Severe Cold: Acetaminophen 500 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per packet (6s) [contains phenylalanine 20 mg/packet, potassium 10 mg/packet, and sodium 19 mg/packet; Lipton green tea and honey lemon flavors]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Syrup, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Theraflu ExpressMax Daytime Severe Cold &amp; Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (245.5 mL) [contains ethanol, potassium 12 mg/15 mL, propylene glycol, sodium 8 mg/15 mL, sodium benzoate; berry flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093664\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093690\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Administer with water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for solution: Dissolve one packet in 240 mL hot water; consume within 10 to 15 minutes. If using microwave, add one packet to 240 mL of cool water and stir briskly before and after heating; do not overheat.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Syrup: Administer using enclosed dosing cup.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow whole; do not crush, chew, or dissolve.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093668\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cold and flu symptoms: </b>Temporary relief of common cold and flu symptoms (eg, cough due to minor throat and bronchial irritation, fever, headache, minor aches and pains, nasal congestion, sinus congestion/pressure, sore throat).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5118570\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093673\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093669\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">OTC labeling: When used for self-medication, do not use with any other drug containing acetaminophen; in combination with or within 14 days of stopping a monoamine oxidase inhibitor (MAOI); if you are hypersensitive to acetaminophen, dextromethorphan, phenylephrine, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093670\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Acetaminophen has been associated with acute liver failure, at times resulting in liver transplant and death. Hepatotoxicity is usually associated with excessive acetaminophen intake and often involves more than one product that contains acetaminophen. Do not exceed the maximum recommended daily dose (&gt;4 g daily). In addition, long-term daily dosing may also result in liver damage in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Serious and potentially fatal skin reactions, including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have occurred rarely with acetaminophen use. Discontinue therapy at the first appearance of skin rash.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage. Avoid ethanol or limit to &lt;3 drinks/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with hepatic impairment or active liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2D6 poor metabolizers: Dextromethorphan is metabolized by hepatic CYP2D6. Poor metabolizers of CYP2D6 may have exaggerated or prolonged effects of dextromethorphan. Increased risk may be seen with concomitant use of potent CYP2D6 inhibitors; use with caution (Abduljalil 2010; Jurica 2012; Sager 2014; Zhou 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; more likely to experience adverse reactions to sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium: Some products may contain sodium; use with caution in sodium restricted patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dosage limit: Limit acetaminophen dose from all sources &lt;4 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication (OTC), discontinue use and notify health care provider if pain, cough, or nasal congestion gets worse or lasts more than 7 days; fever gets worse or lasts &gt;3 days; if any new symptoms or nervousness, dizziness, or sleeplessness occur; if redness or swelling is present; or if cough comes back or occurs with rash or headache that lasts. If sore throat is severe, persists for &gt;2 days, is accompanied or followed by a fever, headache, rash, nausea, or vomiting, contact health care provider. For persistent or chronic cough (as with smoking, asthma, emphysema) or if cough is accompanied by excessive phlegm, consult a health care provider prior to use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093678\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093677\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9292&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hepatotoxic effect of Acetaminophen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.<b> Exceptions: </b>Amobarbital; Butabarbital; Butalbital; Methohexital; PENTobarbital; Secobarbital; Thiopental.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Acetaminophen may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Acetaminophen may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyraPONE: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: May increase the serum concentration of Dextromethorphan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Acetaminophen may increase the serum concentration of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.<b> Exceptions: </b>FluvoxaMINE.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Dextromethorphan. Management: Consider avoiding dextromethorphan in patients taking tipranavir. If combined, monitor closely for increased dextromethorphan effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5093689\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine, potassium, and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132840\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Although not fully elucidated, the analgesic effects are believed to be due to activation of descending serotonergic inhibitory pathways in the CNS. Interactions with other nociceptive systems may be involved as well (Smith 2009). Antipyresis is produced from inhibition of the hypothalamic heat-regulating center.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextromethorphan: Controls cough by depressing the medullary cough center.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine: Causes vasoconstriction of the arterioles of the nasal mucosa.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132841\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324141\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mucinex Fast-Max Cold &amp; Sinus Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (16): $11.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mucinex Fast-Max Cong Headache Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (16): $12.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Robitussin Cold+Flu Daytime Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (20): $6.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Theraflu ExpressMax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20-10-650 mg/30 mL (245.5 mL): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tylenol Cold Max Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg/15 mL (240 mL): $6.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Theraflu Severe Cold Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20-10-500 mg (6): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Comtrex Cold &amp; Cough Max St Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (24): $4.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mapap Cold Formula Multi-Sympt Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (24): $2.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sudafed PE Pressure+Pain+Cough Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (24): $6.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Theraflu ExpressMax Sev Cld/Cg Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (20): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Theraflu Severe Cold Daytime Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15-5-325 mg (24): $4.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Theraflu Severe Cold/Cgh Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (24): $4.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tylenol Cold Max Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5-325 mg (24): $6.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038896\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Panadol Flu &amp; Batuk (ID);</li>\n      <li>Tusedex (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abduljalil K, Frank D, Gaedigk A, et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. <i>Clin Pharmacol Ther</i>. 2010;88(5):643-651. doi: 10.1038/clpt.2010.137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/20881950/pubmed\" target=\"_blank\" id=\"20881950\">20881950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alka-Seltzer Plus Day Cold &amp; Flu capsules (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Morristown, NJ: Bayer Healthcare LLC; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alka-Seltzer Plus Day Severe Sinus Congestion &amp; Cough capsules (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Morristown, NJ: Bayer Healthcare LLC; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo; <i>Ann Pharmacother</i>, 1999, 33(4):506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/10332548/pubmed\" target=\"_blank\" id=\"10332548\">10332548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caldeira D, Costa J, Barra M, Pinto FJ, Ferreira JJ. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. <i>Thromb Res.</i> 2015; 135(1):58-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/25456003/pubmed\" target=\"_blank\" id=\"25456003\">25456003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Comtrex Maximum Strength Cold and Cough Non-Drowsy tablets (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health, Inc; December 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo; <i>J Thromb Haemost</i>, 2003, 1(4):714-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/12871405/pubmed\" target=\"_blank\" id=\"12871405\">12871405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(1):109-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/12523469/pubmed\" target=\"_blank\" id=\"12523469\">12523469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo; <i>JAMA</i>, 1998, 279(9):657-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/9496982/pubmed\" target=\"_blank\" id=\"9496982\">9496982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jurica J, Bartecek R, Zourkova A, et al. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. <i>J Clin Pharm Ther.</i> 2012;37(4):486-490. doi: 10.1111/j.1365-2710.2012.01333.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/22548589/pubmed\" target=\"_blank\" id=\"22548589\">22548589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan D, Bartle WR, and Walker SE, &quot;The Effects of Acetaminophen on Pharmacokinetics and Pharmacodynamics of Warfarin,&quot; <i>J Clin Pharmacol</i>, 1999, 39(1):68-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/9987702 /pubmed\" target=\"_blank\" id=\"9987702 \">9987702 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57:212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee WM, &quot;Drug-Induced Hepatotoxicity,&quot; <i>N Engl J Med</i>, 1995, 333(17):1118-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/7565951 /pubmed\" target=\"_blank\" id=\"7565951 \">7565951 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McClain CJ, Price S, Barve S, et al, &quot;Acetaminophen Hepatotoxicity: An Update,&quot; <i>Curr Gastroenterol Rep</i>, 1999, 1(1):42-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/10980926 /pubmed\" target=\"_blank\" id=\"10980926 \">10980926 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehlisch DR, Aspley S, Daniels SE, et al, &quot;Comparison of the Analgesic Efficacy of Concurrent Ibuprofen and Paracetamol With Ibuprofen or Paracetamol Alone in the Management of Moderate to Severe Acute Postoperative Dental Pain in Adolescents and Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose, Two-Center, Modified Factorial Study,&quot; <i>Clin Ther</i>, 2010, 32(5):882-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/20685496/pubmed\" target=\"_blank\" id=\"20685496\">20685496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sager JE, Lutz JD, Foti RS, et al. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.<i> Clin Pharmacol Ther</i>. 2014;95(6):653-662. doi: 10.1038/clpt.2014.50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/24569517/pubmed\" target=\"_blank\" id=\"24569517\">24569517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shek KL, Chan LN, and Nutescu E, &quot;Warfarin-Acetaminophen Drug Interaction Revisited,&quot; <i>Pharmacotherapy</i>, 1999, 19(10):1153-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/10512064 /pubmed\" target=\"_blank\" id=\"10512064 \">10512064 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith HS. Potential analgesic mechanisms of acetaminophen. <i>Pain Physician</i>. 2009;12(1):269-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/19165309/pubmed\" target=\"_blank\" id=\"19165309\">19165309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sudafed PE Pressure+Pain+Cough tablets (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaka E, Yamazaki K, and Misawa S, &quot;Update: The Clinical Importance of Acetaminophen Hepatotoxicity in Nonalcoholic and Alcoholic Subjects,&quot; <i>J Clin Pharm Ther</i>, 2000, 25(5):325-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/11123483 /pubmed\" target=\"_blank\" id=\"11123483 \">11123483 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Theraflu Daytime Severe Cold &amp; Cough powder (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health Inc; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Theraflu Expressmax Daytime Severe Cold &amp; Cough syrup (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Theraflu Multi Symptom Severe Cold powder (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health Inc; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Theraflu Warming Relief Daytime Multi-Symptom Cold tablets (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health Inc; October 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Theraflu Warming Relief Daytime Severe Cold &amp; Cough syrup (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health Inc; January 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tylenol Cold Max Day liquid (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tylenol Cold Max Day tablets (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Bemt PM, Geven LM, Kuitert NA, et al, &quot;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&quot; <i>Pharm World Sci</i>, 2002, 24(5):201-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/12426965/pubmed\" target=\"_blank\" id=\"12426965\">12426965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vicks Dayquil Cold &amp; Flu Multi-Symptom Relief capsules (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vicks Dayquil Cold &amp; Flu Multi-Symptom Relief liquid (acetaminophen/dextromethorphan/phenylephrine) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. <i>Clin Pharmacokinet</i>. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information/abstract-text/19902987/pubmed\" target=\"_blank\" id=\"19902987\">19902987</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9292 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5093662\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5093666\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5093687\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5093686\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5093688\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F49132843\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F49132844\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5093692\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5093664\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5093690\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5093668\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5118570\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5093673\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5093669\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5093670\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F5093678\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5093677\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5093689\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49132840\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F49132841\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324141\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038896\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9292|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-patient-drug-information\" class=\"drug drug_patient\">Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Patient drug information</a></li></ul></div></div>","javascript":null}